These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 16361541

  • 1. Perturbation of the tumor necrosis factor--related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5.
    Horak P, Pils D, Kaider A, Pinter A, Elandt K, Sax C, Zielinski CC, Horvat R, Zeillinger R, Reinthaller A, Krainer M.
    Clin Cancer Res; 2005 Dec 15; 11(24 Pt 1):8585-91. PubMed ID: 16361541
    [Abstract] [Full Text] [Related]

  • 2. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
    van Geelen CM, Westra JL, de Vries EG, Boersma-van Ek W, Zwart N, Hollema H, Boezen HM, Mulder NH, Plukker JT, de Jong S, Kleibeuker JH, Koornstra JJ.
    J Clin Oncol; 2006 Nov 01; 24(31):4998-5004. PubMed ID: 17075118
    [Abstract] [Full Text] [Related]

  • 3. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells.
    Lane D, Cartier A, L'Espérance S, Côté M, Rancourt C, Piché A.
    Gynecol Oncol; 2004 Jun 01; 93(3):594-604. PubMed ID: 15196850
    [Abstract] [Full Text] [Related]

  • 4. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP.
    Kang J, Bu J, Hao Y, Chen F.
    Prostate Cancer Prostatic Dis; 2005 Jun 01; 8(3):274-9. PubMed ID: 15897917
    [Abstract] [Full Text] [Related]

  • 5. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jégou B, Patard JJ, Guillaudeux T.
    Prostate; 2006 Jun 15; 66(9):987-95. PubMed ID: 16541419
    [Abstract] [Full Text] [Related]

  • 6. Mechanisms of resistance to TRAIL-induced apoptosis in cancer.
    Zhang L, Fang B.
    Cancer Gene Ther; 2005 Mar 15; 12(3):228-37. PubMed ID: 15550937
    [Abstract] [Full Text] [Related]

  • 7. Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor.
    Koyama S, Koike N, Adachi S.
    J Cancer Res Clin Oncol; 2002 Feb 15; 128(2):73-9. PubMed ID: 11862476
    [Abstract] [Full Text] [Related]

  • 8. Identification of interleukin 8 as an inhibitor of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in the ovarian carcinoma cell line OVCAR3.
    Abdollahi T, Robertson NM, Abdollahi A, Litwack G.
    Cancer Res; 2003 Aug 01; 63(15):4521-6. PubMed ID: 12907626
    [Abstract] [Full Text] [Related]

  • 9. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.
    Tomek S, Horak P, Pribill I, Haller G, Rössler M, Zielinski CC, Pils D, Krainer M.
    Gynecol Oncol; 2004 Jul 01; 94(1):107-14. PubMed ID: 15262127
    [Abstract] [Full Text] [Related]

  • 10. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
    Chen S, Liu X, Yue P, Schönthal AH, Khuri FR, Sun SY.
    Mol Pharmacol; 2007 Nov 01; 72(5):1269-79. PubMed ID: 17684158
    [Abstract] [Full Text] [Related]

  • 11. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor.
    van der Sloot AM, Tur V, Szegezdi E, Mullally MM, Cool RH, Samali A, Serrano L, Quax WJ.
    Proc Natl Acad Sci U S A; 2006 Jun 06; 103(23):8634-9. PubMed ID: 16731632
    [Abstract] [Full Text] [Related]

  • 12. The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer.
    Duiker EW, van der Zee AG, de Graeff P, Boersma-van Ek W, Hollema H, de Bock GH, de Jong S, de Vries EG.
    Gynecol Oncol; 2010 Mar 06; 116(3):549-55. PubMed ID: 19959214
    [Abstract] [Full Text] [Related]

  • 13. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors.
    Spierings DC, de Vries EG, Timens W, Groen HJ, Boezen HM, de Jong S.
    Clin Cancer Res; 2003 Aug 15; 9(9):3397-405. PubMed ID: 12960128
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Time sequence of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin treatment is responsible for a complex pattern of synergistic cytotoxicity.
    Kim YH, Lee YJ.
    J Cell Biochem; 2006 Aug 01; 98(5):1284-95. PubMed ID: 16514644
    [Abstract] [Full Text] [Related]

  • 16. Application of flow cytometry to molecular medicine: detection of tumor necrosis factor-related apoptosis-inducing ligand receptors in acute myeloid leukaemia blasts.
    Cappellini A, Mantovani I, Tazzari PL, Grafone T, Martinelli G, Cocco L, Martelli AM.
    Int J Mol Med; 2005 Dec 01; 16(6):1041-8. PubMed ID: 16273284
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Long lasting heat shock stimulation of TRAIL-induced apoptosis in transformed T lymphocytes.
    Moulin M, Arrigo AP.
    Exp Cell Res; 2006 Jun 10; 312(10):1765-84. PubMed ID: 16584728
    [Abstract] [Full Text] [Related]

  • 19. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
    Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B, Schmid RA.
    Cancer Res; 2006 Jun 01; 66(11):5867-74. PubMed ID: 16740726
    [Abstract] [Full Text] [Related]

  • 20. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
    Yamanaka Y, Shiraki K, Inoue T, Miyashita K, Fuke H, Yamaguchi Y, Yamamoto N, Ito K, Sugimoto K, Nakano T.
    Int J Mol Med; 2006 Jul 01; 18(1):41-7. PubMed ID: 16786154
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.